Shanshan Hu Selected Research

Chronobiology Disorders (Circadian Rhythm Disorder)

11/2022	Pu-erh tea increases the metabolite Cinnabarinic acid to improve circadian rhythm disorder-induced obesity.
5/2022	Pu-erh Tea Restored Circadian Rhythm Disruption by Regulating Tryptophan Metabolism.
2/2022	Tea combats circadian rhythm disorder syndrome via the gut-liver-brain axis: potential mechanisms speculated.
11/2021	Ripened Pu-Erh Tea Improved the Enterohepatic Circulation in a Circadian Rhythm Disorder Mice Model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shanshan Hu Research Topics

Disease

13	Neoplasms (Cancer) 01/2022 - 02/2013
9	Cataract (Cataracts) 03/2021 - 04/2010
8	Inflammation (Inflammations) 05/2022 - 01/2017
4	Chronobiology Disorders (Circadian Rhythm Disorder) 11/2022 - 11/2021
4	Glioma (Gliomas) 01/2022 - 09/2020
4	Hepatocellular Carcinoma (Hepatoma) 12/2020 - 02/2013
3	Hyperglycemia 04/2022 - 09/2017
3	AIDS-Related Complex (ARC) 01/2022 - 01/2013
3	Fibrosis (Cirrhosis) 01/2022 - 04/2013
3	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2021
3	Carcinogenesis 10/2021 - 09/2020
2	Obesity 11/2022 - 11/2021
2	Parkinson Disease (Parkinson's Disease) 07/2022 - 01/2020
2	Neoplasm Metastasis (Metastasis) 01/2021 - 02/2013
2	Stomach Neoplasms (Stomach Cancer) 01/2021 - 04/2015
2	Experimental Arthritis 08/2019 - 01/2017
2	Arthritis (Polyarthritis) 08/2019 - 12/2013
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2019 - 01/2019
2	Rheumatoid Arthritis 12/2013 - 04/2013
1	Colonic Neoplasms (Colon Cancer) 05/2022
1	Diabetes Mellitus 04/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 03/2022
1	Hyperuricemia 03/2022
1	Metabolic Diseases (Metabolic Disease) 03/2022
1	Hypertension (High Blood Pressure) 03/2022
1	Gout 03/2022
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022
1	Brain Neoplasms (Brain Tumor) 01/2022
1	Epilepsy (Aura) 01/2022
1	Pain (Aches) 01/2022
1	Colitis 09/2021
1	Hyperthermia 01/2021
1	Alzheimer Disease (Alzheimer's Disease) 01/2021
1	Pulmonary Edema 01/2021
1	Stomatitis 01/2021
1	Wounds and Injuries (Trauma) 01/2021
1	Disease Progression 01/2021

Drug/Important Bio-Agent (IBA)

7	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2011
6	TeaIBA 11/2022 - 09/2021
4	ConnexinsIBA 12/2017 - 04/2010
3	Biomarkers (Surrogate Marker)IBA 07/2022 - 02/2013
3	Long Noncoding RNAIBA 10/2021 - 09/2020
3	Biological ProductsIBA 09/2021 - 02/2013
3	RNA (Ribonucleic Acid)IBA 03/2021 - 09/2020
2	Bile Acids and Salts (Bile Acids)IBA 05/2022 - 11/2021
2	PhytochemicalsIBA 05/2022 - 02/2022
2	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 01/2021
2	semaglutideIBA 01/2022 - 01/2021
2	human MIRN619 microRNAIBA 10/2021 - 11/2020
2	Capsules (Microcapsules)IBA 03/2021 - 12/2020
2	Therapeutic UsesIBA 01/2021 - 12/2013
2	Pharmaceutical PreparationsIBA 01/2021 - 02/2013
2	Competitive Endogenous RNAIBA 11/2020 - 09/2020
2	SynucleinsIBA 01/2020 - 01/2020
2	Glucose (Dextrose)FDA LinkGeneric 09/2019 - 08/2015
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2019 - 01/2018
1	cinnabarinic acidIBA 11/2022
1	MicroRNAs (MicroRNA)IBA 07/2022
1	Neurotransmitter Agents (Neurotransmitter)IBA 05/2022
1	Tryptophan (L-Tryptophan)FDA Link 05/2022
1	CytokinesIBA 04/2022
1	Peptide Hydrolases (Proteases)FDA Link 04/2022
1	Matrix Metalloproteinases (MMPs)IBA 04/2022
1	purineIBA 03/2022
1	PolyphenolsIBA 03/2022
1	Uric Acid (Urate)IBA 03/2022
1	Caffeine (No Doz)FDA LinkGeneric 03/2022
1	FructoseIBA 03/2022
1	C-Reactive ProteinIBA 01/2022
1	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2022
1	dulaglutideIBA 01/2022
1	Glucose Transporter Type 1IBA 01/2022
1	Exenatide (Byetta)FDA Link 01/2022
1	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2022
1	Interleukin-17 (Interleukin 17)IBA 01/2022
1	NitrogenIBA 11/2021
1	Dextran SulfateIBA 09/2021
1	Tight Junction ProteinsIBA 09/2021
1	trilobatinIBA 01/2021
1	N(1)-methyl-2-lysergic acid diethylamide (MIL)IBA 01/2021
1	parecoxibIBA 01/2021
1	saxagliptin FDA Link 01/2021
1	dapagliflozinIBA 01/2021
1	polydopamineIBA 01/2021
1	Circular RNAIBA 01/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2021
1	Hematoxylin (Haematoxylon)IBA 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	Heterogeneous-Nuclear Ribonucleoprotein Group MIBA 01/2021
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2021
1	Notch ReceptorsIBA 12/2020
1	LigandsIBA 12/2020

Therapy/Procedure

7	Therapeutics 01/2022 - 12/2018
4	Drug Therapy (Chemotherapy) 05/2022 - 01/2019
1	Neoadjuvant Therapy 05/2022
1	Radiotherapy 01/2022
1	Immunotherapy 01/2022
1	Perioperative Nursing 01/2022
1	Photothermal Therapy 01/2021
1	Lasers (Laser) 01/2021